NDA 214755 · Alkermes INC
Lumryz
Sodium Oxybate · Oral
OrphanLast checked: Nov 20, 2026Latest source record: Nov 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
May 1, 2023
Approved uses
2
Original approval plus efficacy supplements
Registered trials
59
17 Phase 3, 4 recruiting
FAERS reports
5,012
1,731 serious, 123 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CENTRAL NERVOUS SYSTEM (CNS) DEPRESSION AND ABUSE AND MISUSE Central Nervous System Depression LUMRYZ (sodium oxybate) is a CNS depressant. Clinically significant respiratory depression and obtundation may occur in patients treated with LUMRYZ at recommended doses [see Warnings and Precautions (5.1) ] . Many patients who received sodium oxybate during clinical trials in narcolepsy were receiving central nervous system stimulants [see Clinical Trials (14) ] . Abuse and Misuse LUMRYZ (sodium oxybate) is the sodium salt of gamma-hydroxybutyrate (GHB). Abuse or misuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death [see Warnings and Precautions (5.2) ] . Because of the risks of CNS depression and abuse and misuse,...
What it is approved for
From the label in effect Sep 8, 2026.
LUMRYZ is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. LUMRYZ is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy ( 1 ).
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 16, 2024 Supplement 6 · Efficacy OrphanLetterLabelMedication Guide
- May 1, 2023 Original approval · Type 3 - New Dosage Form OrphanLetterLabelREMS
4 products under this application
- LUMRYZ · SODIUM OXYBATE 7.5GM/PACKET · FOR SUSPENSION, EXTENDED RELEASE, ORAL · Prescription
- LUMRYZ · SODIUM OXYBATE 4.5GM/PACKET · FOR SUSPENSION, EXTENDED RELEASE, ORAL · Prescription
- LUMRYZ · SODIUM OXYBATE 9GM/PACKET · FOR SUSPENSION, EXTENDED RELEASE, ORAL · Prescription
- LUMRYZ · SODIUM OXYBATE 6GM/PACKET · FOR SUSPENSION, EXTENDED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Oxybate" as an intervention, any sponsor and status, largest first.
- A Safety and Efficacy Study of Xyrem® (Sodium Oxybate) to Treat Fibromyalgia.Pivotal-lookingCompleted
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT00423813 · 573 participants · Start Dec 2006 · Primary completion Apr 2009
Drug: placebo; Xyrem® · For: Fibromyalgia
Sites: Auburn, Alabama; Birmingham, Alabama; Montgomery, Alabama · 116 sites in all
- Safety and Efficacy Study of Xyrem® (Sodium Oxybate) in Subjects With Fibromyalgia.Pivotal-lookingCompleted
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT00423605 · 560 participants · Start Dec 2006 · Primary completion Jan 2010
Drug: Xyrem® · For: Fibromyalgia
Sites: Anniston, Alabama; Auburn, Alabama; Phoenix, Arizona · 91 sites in all
- A Safety and Efficacy Study of Xyrem® in Subjects With FibromyalgiaPivotal-lookingCompleted
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT00371137 · 548 participants · Start Aug 2006 · Primary completion Sep 2008
Drug: Xyrem®; Placebo · For: Fibromyalgia
Sites: Anniston, Alabama; Huntsville, Alabama; Phoenix, Arizona · 70 sites in all
- Sodium Oxybate for Postoperative Sleep Disturbance After Thoracic SurgeryPivotal-lookingRecruiting
Jingsheng LouAcademic, hospital or other
NCT07794982 · 360 participants (planned) · Start Sep 1, 2026 · Primary completion Dec 2027
Drug: sodium oxybate; Placebo · For: Thoracic Surgical Procedures
Sites: Beijing, China
- Evaluation of the Efficacy of Sodium Oxybate in the Long-term Maintenance of Abstinence in Alcoholic PatientsPivotal-lookingCompleted
Laboratorio Farmaceutico Ct S.r.l.Industry
NCT04648423 · 314 participants · Start Jul 23, 2001 · Primary completion Mar 2011
Drug: Sodium Oxybate; Placebo · For: Alcohol Use Disorder (AUD); Alcohol Dependence
- Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in NarcolepsyPivotal-lookingCompleted
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT00066170 · 231 participants · Start Apr 2003 · Primary completion Jul 2004
Drug: Xyrem; Xyrem Placebo and 2 more · For: Narcolepsy
Sites: Phoenix, Arizona; Fullerton, California; Los Angeles, California · 40 sites in all
- Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in NarcolepsyPivotal-lookingCompleted
AvadelIndustry
NCT02720744 · 212 participants · Start Nov 17, 2016 · Primary completion Mar 25, 2020
Drug: FT218; Placebo · For: Excessive Daytime Sleepiness; Cataplexy; Narcolepsy
Sites: Anniston, Alabama; Auburn, Alabama; Birmingham, Alabama · 57 sites in all
- A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With CataplexyPivotal-lookingCompleted
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT03030599 · 201 participants · Start Mar 14, 2017 · Primary completion Jan 24, 2019
Drug: JZP-258 · For: Narcolepsy With Cataplexy
Sites: Orange, California; Stanford, California; Boulder, Colorado · 25 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- somnolence896
- insomnia872
- middle insomnia807
- nausea748
- product dose omission issue645
- fatigue612
- drug ineffective567
- initial insomnia454
- dizziness405
- anxiety401
- intentional dose omission384
- feeling abnormal377
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 27 |
| 2011 | 15 |
| 2012 | 12 |
| 2013 | 5 |
| 2014 | 5 |
| 2015 | 17 |
| 2016 | 16 |
| 2017 | 22 |
| 2018 | 52 |
| 2019 | 39 |
| 2020 | 19 |
| 2021 | 28 |
| 2022 | 28 |
| 2023 | 551 |
| 2024 | 2,469 |
| 2025 | 1,233 |
| 2026 | 467 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lumryz (Sodium Oxybate)
2024 spending
$16.1M
Beneficiaries
233
1,219 claims
Per beneficiary
$69,247
$492.99 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $2,175,379 |
| 2024 | $16,134,521 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline.
Maski K, Trotti LM, Kotagal S, et al. · J Clin Sleep Med 2021 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment.
Maski K, Trotti LM, Kotagal S, et al. · J Clin Sleep Med 2021 · Meta-Analysis, Research Support, N.I.H., Extramural
- Pharmacological treatment for obstructive sleep apnea: A systematic review and meta-analysis.
Nobre ML, Sarmento ACA, de Oliveira PF, et al. · Clinics (Sao Paulo) 2024 · Meta-Analysis, Systematic Review
- Evaluating pitolisant as a narcolepsy treatment option.
de Biase S, Pellitteri G, Gigli GL, et al. · Expert Opin Pharmacother 2021 · Comparative Study, Systematic Review
- Nocturnal sodium oxybate increases the anterior cingulate cortex magnetic resonance glutamate signal upon awakening.
Dornbierer DA, Zölch N, Baur DM, et al. · J Sleep Res 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- A minimal clinically important difference for the sleep inertia visual analog scale in idiopathic hypersomnia.
Bogan RK, Fuller DS, Whalen M, et al. · J Clin Sleep Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Alkermes INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.